Taiho acquires Yondelis for Japan
This article was originally published in Scrip
Taiho has acquired exclusive Japanese development and marketing rights to PharmaMar's antitumour compound Yondelis (trabectedin). The Spanish Zeltia group's subsidiary will receive ¥1 billion ($10.2 million) up front, plus milestones and double-digit sales royalties.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.